CTOs on the Move

Inteprod

www.inteprod.com

 
Inteprod LLC is a Norristown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.inteprod.com
  • 970 Rittenhouse Rd
    Norristown, PA USA 19403
  • Phone: 610.650.9002

Executives

Name Title Contact Details

Similar Companies

Satellite Healthcare

Making Life Better for Those Living with Kidney Disease. For nearly 40 years, our mission has remained unchanged. From the patient chair side to the boardroom, this powerful yet practical principle guides our daily clinical work as well as our leadership decisions.

Sameday Health

Sameday Health is dedicated to healthcare as a complete experience, not simply a service. Our purpose is to create healthcare that centers around the client, combining a human approach with intuitive technology. We offer quality, personalized care wherever you are including in our clinics or at your door.

Health Castle

Health Castle is a Port Coquitlam, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Banyan Hypnosis Ctr-Training

Banyan Hypnosis Ctr-Training is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.